How can we engineer car t cells to overcome resistance?

Maya Glover, Stephanie Avraamides, John Maher*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.

Original languageEnglish
Pages (from-to)175-198
Number of pages24
JournalBiologics: Targets and Therapy
Publication statusPublished - 2021


  • Cancer
  • Chimeric antigen receptor
  • Immunotherapy
  • Resistance
  • T-cell


Dive into the research topics of 'How can we engineer car t cells to overcome resistance?'. Together they form a unique fingerprint.

Cite this